PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial (CROSBI ID 662056)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Chia, S.K.L. ; Martin, M. ; Holmes, F.A. ; Ejlertsen, B. ; Delaloge, S. ; Moy, B. ; Iwata, H. ; von Minckwitz, G. ; Mansi, J. ; Barrios, C.H. ; Gnant, M. ; Tomašević, Z. ; Denduluri, N. ; Šeparović, Robert ; Kim, Jakobsen, E.H. ; Harvey, V. ; Robert, N. ; Smith, J.I.I. ; Harker, G. ; Lalani, A.S. ; Zhang, B. ; Eli, L.D. ; Chan, A.
engleski
PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early- stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial
One year of neratinib treatment after trastuzumab- based adjuvant therapy significantly improves iDFS after 5 years in patients with early-stage HER2+ breast cancer. From this modest-sized exploratory cohort, it appears that PIK3CA may be a biomarker for differential sensitivity to neratinib after 1 year of trastuzumab in the adjuvant setting.These exploratory results should be validated in a larger subset.
neratinib ; trastuzumab ; ExteNET trial ; early HER2 positive breast cancer
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
PD3-12-PD3-12.
2018.
nije evidentirano
objavljeno
10.1158/1538-7445.SABCS17-PD3-12
Podaci o matičnoj publikaciji
Cancer research (Baltimore)
Van Dang, Chi
Philadelphia (PA): American Association for Cancer Research
0008-5472
1538-7445
Podaci o skupu
San Antonio Breast Cancer Symposium (SABCS) 2018
poster
04.12.2018-08.12.2018
San Antonio (TX), Sjedinjene Američke Države
Povezanost rada
Kliničke medicinske znanosti
